Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Large Growth in Short Interest

Silexion Therapeutics Corp (NASDAQ:SLXN) saw a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 119,287 shares, an increase of 460.5% from the July 30th total of 21,284 shares. Approximately 2.2% of the shares of the company are sold short. Based on an average daily trading volume, of 927,154 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SLXN. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Monday, June 15th. Maxim Group downgraded shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold”.

Silexion Therapeutics Stock Up 0.5%

Shares of Silexion Therapeutics stock traded up $0.00 during trading on Friday, reaching $0.36. The company’s stock had a trading volume of 29,710 shares, compared to its average volume of 324,710. Silexion Therapeutics has a 52 week low of $0.35 and a 52 week high of $80.00. The firm has a market cap of $2.01 million, a PE ratio of -0.01 and a beta of -0.25. The business’s 50-day moving average price is $1.90 and its 200-day moving average price is $7.37.

Silexion Therapeutics (NASDAQ:SLXN) last issued its quarterly earnings data on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, topping the consensus estimate of ($21.20) by $16.03. Equities analysts predict that Silexion Therapeutics will post -45.5 earnings per share for the current year.

Institutional Investors Weigh In On Silexion Therapeutics

A hedge fund recently bought a new position in Silexion Therapeutics stock. Ancora Advisors LLC purchased a new position in shares of Silexion Therapeutics Corp (NASDAQ:SLXN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 30,000 shares of the company’s stock, valued at approximately $31,000. Ancora Advisors LLC owned approximately 7.14% of Silexion Therapeutics at the end of the most recent reporting period. Institutional investors own 10.95% of the company’s stock.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.